Redeye: Efecte - Strong Momentum in New Sales
Redeye retains its positive view of Efecte following the Q2 report. New sales was strong and compensated for a somewhat softer NRR, although still at a healthy level. Efecte sticks to its 2023 guidance, and we keep our forecasts roughly unchanged and retain our Base Case.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/